Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
Increased risk of multiple sclerosis relapse after in vitro fertilisation.
Gray matter involvement in multiple sclerosis.
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Acid-sensing ion channels: trafficking and synaptic function.
Deletion of IL-4Rα in the BALB/c mouse is associated with altered lesion topography and susceptibility to experimental autoimmune encephalomyelitis.
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.
Purkinje cell pathology and loss in multiple sclerosis cerebellum.
Natalizumab discontinuation and disease restart in pregnancy: a case series.
Heat shock protein 27 in multiple sclerosis relapses.
Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties.
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.
Value of NMO-IgG determination at the time of presentation as CIS.
Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen.
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Merck KGaA Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod (ONO-4641)
Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.
Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs.
XIMINO (minocycline hydrochloride) capsule, extended release [Ranbaxy Laboratories Inc.]
Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.
Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.
Decreased signal transducers and activators of transcription (STAT) protein expression in lymphatic organs during EAE development in mice.
Increased promoter methylation of the immune regulatory gene SHP-1 in leukocytes of multiple sclerosis subjects.
Adult mesenchymal stem cell therapy for myelin repair in Multiple Sclerosis.
Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab.

Pages